News | Clinical Decision Support | March 11, 2015

Point of Care Decision Support Anticoagulation Software Helps Reduce Hospital Re-Admissions

Software is designed and developed in association with national patient safety guidelines to reduce adverse events and re-admissions

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Image courtesy of Point of Care Decision Support

March 11, 2015 — Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation (AC) drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.

PCDS AC meets the key recommendations of The Joint Commission, the Centers for Medicare and Medicaid Services (CMS) and the Anticoagulation EHR (Electronic Health Record) Task Force. The system could be beneficial in light of new target-specfic oral anticoagulants (TSOAC) drugs coming onto the market, changing AC therapy protocols and more stringent regulatory guidelines.

Key benefits and outcomes of using PCDS AC include:

Patient Safety and Cost Savings: Warfarin-related adverse drug events (myocardial infarctions, strokes, major bleeds, etc.) are reduced by consistently achieving time-in-therapeutic range (TTR) above 70 percent per CMS recommendations.

Patient Safety & Revenue Generation: The PCDS AC system brings together the ACCP Antithrombotic guidelines, risk ratings like CHA2DS2-VASc, HAS-BLED, HEMORR2HAGES, drug-drug interactions, and other evidence-based research to automatically identify high risk patients and manage their AC care end-to-end.  This also provides an opportunity to identify new patients who may benefit from proactive AC therapy and reduce their overall risk of stroke.

Patient Satisfaction: The PCDS AC system incorporates full TSOAC therapy and workflow, which allow for expanded paradigms of anticoagulant management. These new TSOAC agents require far less blood testing, which is a major benefit for patients.  In addition, the system provides data on the efficacy of TSOACs, leading to improved patient care and, ultimately, cost savings surrounding adverse events.

Fulfill CMS Meaningful Use Stages 2 & 3: Provides ability to fulfill CMS MU-2 criteria for quality of Warfarin dosing at a system level with TTR > 70 percent.  Achieves MU-3 measures by improving population health, provides decision support for high priority health conditions, and provides patient self-management tools via a mobile patient engagement application.

Point of Care Decision Support provides any healthcare organization a free, customized demonstration and business case report for its anticoagulant patient population. 

For more information:

Related Content

LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab | September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab | August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab | July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab | June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Videos | EP Lab | May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Videos | EP Lab | May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Overlay Init